Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Rd, Nanjing 210029, People's Republic of China.
J Cancer Res Clin Oncol. 2012 Jun;138(6):1057-62. doi: 10.1007/s00432-012-1179-1. Epub 2012 Mar 4.
Cytokine-induced killer (CIK) cells exert high impact on adoptive immunotherapeutic approaches for malignant tumors. This study aimed to evaluate the effect of adjuvant immunotherapy with CIK cells on the prognosis of solid tumor.
Peripheral blood mononuclear cells were collected by a blood cell separator from 40 patients, then expanded by priming them with interferon-gamma followed by monoclonal antibody against CD3 and interleukin-2 the next day. The phenotypic patterns of CIK cells were characterized by flow cytometry on days 0, 7, 10, 14 and 21 of incubation, respectively. Then, 5 ml of venous blood was obtained from 40 patients before and after CIK cells were transfused into patients to assess the influence of CIK cells on the percentages of effector cells.
After 14 days of incubation in vitro, the percentages of CD3(+), CD8(+), CD3(+) and CD56(+) increased significantly (P < 0.05). The clinical symptoms of 40 patients were improved apparently. The 6-month, 1-year and 3-year overall survival rates were 70.0, 60.0 and 57.5%, respectively.
Our results indicated that CIKs immunotherapy can be an effective adjuvant instrument of the routine therapy of malignancy.
细胞因子诱导的杀伤（CIK）细胞对恶性肿瘤的过继免疫治疗具有重要影响。本研究旨在评估 CIK 细胞辅助免疫治疗对实体瘤预后的影响。
采用血细胞分离机从 40 例患者中采集外周血单个核细胞，第 1 天用干扰素-γ预刺激，第 2 天用抗 CD3 单克隆抗体和白细胞介素-2刺激，进行体外扩增。分别在培养的第 0、7、10、14 和 21 天，通过流式细胞术对 CIK 细胞的表型模式进行特征分析。然后，在向患者输注 CIK 细胞前后，从 40 例患者中抽取 5ml 静脉血，评估 CIK 细胞对效应细胞百分比的影响。
体外培养 14 天后，CD3(+)、CD8(+)、CD3(+)和 CD56(+)的百分比显著增加（P<0.05）。40 例患者的临床症状明显改善。6 个月、1 年和 3 年的总生存率分别为 70.0%、60.0%和 57.5%。
我们的结果表明，CIK 免疫治疗可以作为恶性肿瘤常规治疗的有效辅助手段。
